OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	286
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	242
The potential value of 5-androstenediol in countering acute radiation syndrome	213
Contents page	201
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	155
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	154
On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives	141
Computational modeling approaches and regulatory pathways for drug combinations	134
Tubulin targeting agents and their implications in non-cancer disease management	130
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	124
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	123
Antibody–drug conjugates: What drives their progress?	122
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	103
CIPDB: A biological structure databank for studying cation and π interactions	103
Gastroretentive drug delivery systems: A holy grail in oral delivery	102
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	98
The recent progress of deep-learning-based in silico prediction of drug combination	97
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	95
Bridging data and drug development: Machine learning approaches for next-generation ADMET prediction	94
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	92
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	91
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	88
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	88
Models and approaches to comprehend and address glial inflammation following spinal cord injury	87
General aspects of powder rheology applied to pharmaceutical formulations	86

Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	85
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	83
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	82
Molecular approaches for the treatment and prevention of Friedreich's ataxia	79
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	78
Global landscape and translational trajectories of flavonoid-based wound-healing research	78
Organoids in modelling infectious diseases	77
Targeted protein degradation: current molecular targets, localization, and strategies	75
Regulatory approvals of therapeutic biologics: continuing progress or plateauing out compared with those of small molecules?	74
Steps toward nebulization in-use studies to understand the stability of new biological entities	72
Gaps between medical biology and AI drug discovery	72
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	72
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	66
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	65
Caught between a ROCK and a hard place: current challenges in structure-based drug design	65
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	65
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	64
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	64
Recent advances towards overcoming the blood–brain barrier	63
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	63
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	60
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	60
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	60
MRI assessment of cerebral perfusion in clinical trials	59
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	59
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	59
Pathogenic TDP-43 in amyotrophic lateral sclerosis	59
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	58
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	58
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	57
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	57
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	57
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	57
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	57